Ultragenyx Pharmaceutical, Inc. (RARE) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Amicus Therapeutics, Inc.

Madrigal Pharmaceuticals, Inc.

ACADIA Pharmaceuticals, Inc.

Prestige Consumer Healthcare, Inc.

Corcept Therapeutics, Inc.

Cytokinetics, Inc.

Ultragenyx Pharmaceutical, Inc.

Cerevel Therapeutics Holdings, Inc.

Akero Therapeutics, Inc.

MoonLake Immunotherapeutics

Bausch Health Cos., Inc.

Why is Ultragenyx Pharmaceutical, Inc. ?

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -28.85%, its profits have risen by 11.9%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -28.85% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ultragenyx Pharmaceutical, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Ultragenyx Pharmaceutical, Inc.

-21.71%

-0.39

50.95%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

30.79%

EBIT Growth (5y)

-6.22%

EBIT to Interest (avg)

-10.77

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

2.49

Sales to Capital Employed (avg)

0.44

Tax Ratio

0.45%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

24.36

EV to EBIT

-7.54

EV to EBITDA

-8.10

EV to Capital Employed

7.70

EV to Sales

6.56

PEG Ratio

Dividend Yield

ROCE (Latest)

-102.05%

ROE (Latest)

-377.52%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -421.25 MM

RAW MATERIAL COST(Y)

Fallen by -1.92% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 2.89 times

NET SALES(Q)

Highest at USD 166.5 MM

OPERATING PROFIT(Q)

Highest at USD -99.27 MM

OPERATING PROFIT MARGIN(Q)

Highest at -59.62 %

PRE-TAX PROFIT(Q)

Highest at USD -114 MM

NET PROFIT(Q)

Highest at USD -114.94 MM

EPS(Q)

Highest at USD -1.17

-2What is not working for the Company

CASH AND EQV(HY)

Lowest at USD 999.54 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.22 times

Here's what is working for Ultragenyx Pharmaceutical, Inc.

Operating Cash Flow

Highest at USD -421.25 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Highest at USD 166.5 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD -99.27 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -59.62 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD -114 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -114.94 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -1.17

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Inventory Turnover Ratio

Highest at 2.89 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -1.92% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Ultragenyx Pharmaceutical, Inc.

Cash and Eqv

Lowest at USD 999.54 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 5.22 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio